The Eli Lilly case against Empower Pharmacy tests a key strategy that's allowed compounding pharmacies to continue to produce versions of wildly popular drugs.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Houston-based Empower Pharmacy rejected Eli Lilly's claims of false advertising in a New Jersey federal court.

The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and weight loss medications known as GLP-1s, arguing this week in federal court ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore AI-driven drug candidates for muscle health. This innovative move ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might ...

Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month. Encouraging data on GLP-1 treatments in its pipeline could help give the stock a big boost. Concerns about ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.